Edition:
United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

14.35USD
2:45pm GMT
Change (% chg)

$-0.10 (-0.69%)
Prev Close
$14.45
Open
$14.40
Day's High
$14.40
Day's Low
$14.30
Volume
3,161
Avg. Vol
50,679
52-wk High
$14.85
52-wk Low
$5.50

Select another date:

Thu, Nov 9 2017

BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68

* Stemline Therapeutics reports third quarter 2017 financial results

BRIEF-Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​

* Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​

BRIEF-Stemline Therapeutics files for mixed shelf offering of up to $175 mln

* Stemline Therapeutics Inc files for mixed shelf offering of up to $175 million - SEC filing‍​ Source text: (http://bit.ly/2wFKm1k) Further company coverage:

BRIEF-Stemline Therapeutics Q2 loss per share $0.66

* Stemline Therapeutics reports second quarter 2017 financial results

BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN

* Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN and safety experience across multiple indications, today at EHA

Select another date: